Syndicate content

Archive - Apr 23, 2020


Pre-Existing Diabetes Reversed in Mice Using Genetically-Edited Stem Cells (iPSCs) Derived from Patient with Wolfram Syndrome, a Form of Diabetes Caused by Mutations in Single Gene; CRISPR Corrects Genetic Defect So Cells Can Normalize Blood Sugar

Using induced pluripotent stem cells (iPSCs) produced from the skin of patients with a rare, monogenic form of insulin-dependent diabetes called Wolfram syndrome, researchers transformed the human stem cells into insulin-producing cells and used the gene-editing tool CRISPR/Cas9 to correct the genetic defect that had caused the syndrome. They then implanted the cells into lab mice with streptozocin-induced diabetes and cured the generally unrelenting diabetes in those mice. The findings, from researchers at Washington University School of Medicine in St. Louis suggest the CRISPR/Cas9 technique may hold promise as a treatment for diabetes, particularly the forms caused by a single gene mutation, and it also may be useful one day in some patients with the more common forms of diabetes, such as type 1 and type 2. The study was published online on April 22, 2020 in Science Translational Medicine. The article is titled “Gene-Edited Human Stem Cell-Derived ß Cells from a Patient with Monogenic Diabetes Reverse Pre-Existing Diabetes in Mice.” Patients with Wolfram syndrome develop diabetes during childhood or adolescence and quickly require insulin-replacement therapy, requiring insulin injections multiple times each day. Most go on to develop problems with vision and balance, as well as other issues, and in many patients, the syndrome contributes to an early death. "This is the first time CRISPR has been used to fix a patient's diabetes-causing genetic defect and successfully reverse diabetes," said co-senior investigator Jeffrey R. Millman, PhD, an Assistant Professor of Medicine and of Biomedical Engineering at Washington University School of Medicine. "For this study, we used cells from a patient with Wolfram syndrome because, conceptually, we knew it would be easier to correct a defect caused by a single gene.

MIT Scientists & Colleagues Identify Cells Likely Targeted by COVID-19 Virus: Specific Cells in Nasal Passages, Lungs, and Intestines; Team Also Shows That Interferon Activates ACE2 Receptor That CORVID-19 Binds to Gain Entry to Cells

Researchers at MIT; the Broad Institute of MIT and Harvard; and the Ragon Institute of MGH, MIT, and Harvard; along with colleagues from around the world, have identified specific types of cells that appear to be targets of the coronavirus that is causing the COVID-19 pandemic. Using existing data on the RNA found in different types of cells, the researchers were able to search for cells that express the two proteins (ACE2 & TMRSS) that help the SARS-CoV-19 virus enter human cells. They found subsets of cells in the lung, the nasal passages, and the intestine that express RNA for both of these proteins much more than other cells. The researchers hope that their findings will help guide scientists who are working on developing new drug treatments or testing existing drugs that could be repurposed for treating COVID-19. "Our goal is to get information out to the community and to share data as soon as is humanly possible, so that we can help accelerate ongoing efforts in the scientific and medical communities," says Alex K. Shalek, PhD, the Pfizer-Laubach Career Development Associate Professor of Chemistry at MIT, a core member of MIT's Institute for Medical Engineering and Science (IMES), an extramural member of the Koch Institute for Integrative Cancer Research, an associate member of the Ragon Institute, and an institute member at the Broad Institute. Dr. Shalek and Jose Ordovas-Montanes, PhD, a former MIT postdoc who now runs his own lab at Boston Children's Hospital, are the senior authors of the study, which was published online on April 21, 2020 in Cell (